Baillie Gifford - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 226 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.

Quarter-by-quarter ownership
Baillie Gifford ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q1 2023$4,612
-13.4%
1150.0%0.00%
Q4 2022$5,328
+6.6%
1150.0%0.00%
Q3 2022$5,000
-28.6%
1150.0%0.00%
Q2 2022$7,000
-12.5%
1150.0%0.00%
Q1 2022$8,000
-20.0%
1150.0%0.00%
Q4 2021$10,0000.0%1150.0%0.00%
Q3 2021$10,000
-9.1%
1150.0%0.00%
Q2 2021$11,000
-15.4%
1150.0%0.00%
Q1 2021$13,000
-13.3%
115
+8.5%
0.00%
Q4 2020$15,0001060.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2023
NameSharesValueWeighting ↓
EcoR1 Capital, LLC 497,899$31,617,0003.20%
HIGHLINE CAPITAL MANAGEMENT, L.P. 390,453$24,794,0001.81%
First Light Asset Management, LLC 180,017$11,431,0001.59%
Rock Springs Capital Management LP 580,000$36,830,0001.33%
Capital Impact Advisors, LLC 36,165$2,244,0000.82%
SECTOR GAMMA AS 79,653$5,058,0000.81%
Verity Asset Management, Inc. 7,193$457,0000.51%
Opus Point Partners Management, LLC 5,064$322,0000.48%
Capital International Sarl 52,000$3,302,0000.46%
PACIFIC VIEW ASSET MANAGEMENT, LLC 6,216$394,0000.43%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders